User login
Key clinical point: Once-weekly dulaglutide was superior to placebo in improving glycemic control through 26 weeks in youths with inadequately controlled type 2 diabetes (T2D) who were being treated with or without metformin or basal insulin.
Major finding: At 26 weeks, 0.75 mg and 1.5 mg dulaglutide vs. placebo led to a significant reduction in mean glycated hemoglobin (A1c) level (estimated treatment difference −1.2% and −1.5%, respectively), in addition to a significant increase in the proportion of patients achieving an A1c level of <7.0% (all P < .001) and a consistent safety profile.
Study details: The data come from the AWARD-PEDS trial including 154 patients with T2D treated with lifestyle modification alone or metformin with or without basal insulin and who were randomly assigned to receive once-weekly dulaglutide or placebo for 26 weeks.
Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving grants or contracts or serving as consultants or on safety and data monitoring boards for various sources, including Eli Lilly. D Cox declared being an employee of and holding stocks or stock options in Eli Lilly.
Source: Arslanian SA et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022 (Jun 4). Doi: 10.1056/NEJMoa2204601
Key clinical point: Once-weekly dulaglutide was superior to placebo in improving glycemic control through 26 weeks in youths with inadequately controlled type 2 diabetes (T2D) who were being treated with or without metformin or basal insulin.
Major finding: At 26 weeks, 0.75 mg and 1.5 mg dulaglutide vs. placebo led to a significant reduction in mean glycated hemoglobin (A1c) level (estimated treatment difference −1.2% and −1.5%, respectively), in addition to a significant increase in the proportion of patients achieving an A1c level of <7.0% (all P < .001) and a consistent safety profile.
Study details: The data come from the AWARD-PEDS trial including 154 patients with T2D treated with lifestyle modification alone or metformin with or without basal insulin and who were randomly assigned to receive once-weekly dulaglutide or placebo for 26 weeks.
Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving grants or contracts or serving as consultants or on safety and data monitoring boards for various sources, including Eli Lilly. D Cox declared being an employee of and holding stocks or stock options in Eli Lilly.
Source: Arslanian SA et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022 (Jun 4). Doi: 10.1056/NEJMoa2204601
Key clinical point: Once-weekly dulaglutide was superior to placebo in improving glycemic control through 26 weeks in youths with inadequately controlled type 2 diabetes (T2D) who were being treated with or without metformin or basal insulin.
Major finding: At 26 weeks, 0.75 mg and 1.5 mg dulaglutide vs. placebo led to a significant reduction in mean glycated hemoglobin (A1c) level (estimated treatment difference −1.2% and −1.5%, respectively), in addition to a significant increase in the proportion of patients achieving an A1c level of <7.0% (all P < .001) and a consistent safety profile.
Study details: The data come from the AWARD-PEDS trial including 154 patients with T2D treated with lifestyle modification alone or metformin with or without basal insulin and who were randomly assigned to receive once-weekly dulaglutide or placebo for 26 weeks.
Disclosures: This study was funded by Eli Lilly and Company. Some authors declared receiving grants or contracts or serving as consultants or on safety and data monitoring boards for various sources, including Eli Lilly. D Cox declared being an employee of and holding stocks or stock options in Eli Lilly.
Source: Arslanian SA et al. Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med. 2022 (Jun 4). Doi: 10.1056/NEJMoa2204601